Clinical Study | Open Access
Kohzo Takebayashi, Rika Naruse, Yoshimasa Aso, Toshihiko Inukai, "The Effect of Amlodipine on Oxidative Stress in Patients with Type 2 Diabetes", SRX Medicine, vol. 2010, Article ID 326840, 5 pages, 2010. https://doi.org/10.3814/2010/326840
The Effect of Amlodipine on Oxidative Stress in Patients with Type 2 Diabetes
Background. Amlodipine, a calcium channel blocker, is reported to have an antioxidative effect in vitro, but whether such an effect occurs clinically is unknown. The purpose of the study was to investigate the effect of amlodipine (5 mg/day) on oxidative stress by measuring urinary 8-iso-prostaglandin F2 (8-iso-PGF2), an oxidative stress marker, in patients with type 2 diabetes. The anti-oxidative effect of amlodipine was also assessed using the levels of high-sensitivity C-reactive protein (hsCRP) and fibrinogen. Patients and Methods. Seventeen consecutive patients with type 2 diabetes complicated by hypertension were prospectively enrolled in the study. These patients received amlodipine (5 mg/day) over a 3-month period and various markers were measured before and at the end of this period. Results. Urinary 8-iso-PGF2 showed a tendency to decrease, but the change was not statistically significant (). The patients were divided into two groups according to the baseline level of urinary 8-iso-PGF2, and a significant decrease in 8-iso-PGF2 was found in the group () with a relatively high baseline 8-iso-PGF2. There were no changes in hsCRP, fibrinogen, and plasminogen activator inhibitor-1. Significant decreases in systolic and diastolic blood pressure were observed (, , resp.). Conclusion. The results show that amlodipine (5 mg/day) may provide a clinically useful anti-oxidative effect, based on evaluation of urinary 8-iso-PGF2.
- P. Libby, “Current concepts of the pathogenesis of the acute coronary syndromes,” Circulation, vol. 104, no. 3, pp. 365–372, 2001.
- A. Warnholtz, G. Nickenig, E. Schulz et al., “Increased NADH-oxidase-mediated superoxide production. In the early stages of atherosclerosis evidence for involvement of the renin-angiotensin system,” Circulation, vol. 99, no. 15, pp. 2027–2033, 1999.
- R. P. Mason, M. F. Walter, M. W. Trumbore, E. G. Olmstead Jr., and P. E. Mason, “Membrane antioxidant effects of the charged dihydropyridine calcium agonist amlodipine,” Journal of Molecular Cellular Cardiology, vol. 31, no. 11, pp. 275–281, 1999.
- T. Yu, I. Morita, K. Shimokado, T. Iwai, and M. Yoshida, “Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction,” Hypertension, vol. 42, no. 3, pp. 329–334, 2003.
- C. Patrono and G. A. FitzGerald, “Isoprostanes: potential markers of oxidant stress in atherothrombotic disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2309–2315, 1997.
- M. P. Reilly, D. Praticó, N. Delanty et al., “Increased formation of distinct isoprostanes in hypercholesterolemia,” Circulation, vol. 98, no. 25, pp. 2822–2828, 1998.
- K. Takebayashi, S. Matsumoto, Y. Aso, and T. Inukai, “Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2214–2217, 2006.
- H. Helmersson and S. Basu, “-isoprostane excretion rate and diurnal variation in human urine,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 61, no. 3, pp. 203–205, 1999.
- K. Takebayashi, Y. Aso, and T. Inukai, “Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes,” Metabolism, vol. 53, no. 6, pp. 693–699, 2004.
- G. Davì, G. Ciabattoni, A. Consoli et al., “In vivo formation of 8-iso-prostaglandin and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation,” Circulation, vol. 99, no. 2, pp. 224–229, 1999.
- J. Nourooz-Zadeh, J. Tajaddini-Sarmadi, S. McCarthy, D. J. Betteridge, and S. P. Wolff, “Elevated levels of authentic plasma hydroperoxides in NIDDM,” Diabetes, vol. 44, no. 9, pp. 1054–1058, 1995.
- T. F. Luscher, R. R. Wenzel, P. Moreau, and H. Takese, “Vascular protective effects of ACE inhibitors ans calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular disease,” Cardiovascular Drugs and Therapy, vol. 9, no. 8, supplement 3, pp. 509–523, 1995.
- X. Zhang and T. H. Hintze, “Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent,” Circulation, vol. 97, no. 6, pp. 576–580, 1998.
- K. Jamerson, M. A. Weber, G. L. Bakris et al., “Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients,” The New England Journal of Medicine, vol. 359, no. 23, pp. 2417–2428, 2008.
Copyright © 2010 Kohzo Takebayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.